Gold Prices Hit Four-Week Low Amid Dollar Strength and Geopolitical Tensions
Gold has fallen over 2% this week and dropped 17% since late February as the stronger US dollar and rising interest rate expectations weigh on precious metal valuations.
Top gainers, losers, and volume shockers
336 articles
Gold has fallen over 2% this week and dropped 17% since late February as the stronger US dollar and rising interest rate expectations weigh on precious metal valuations.
Indian equity markets extend gains with Nifty and Sensex climbing higher on strong banking and auto sector performance, though global volatility remains a key concern.
Indian equities maintain upward momentum with banking and auto sectors rallying. Seven key stocks grab investor attention amid significant corporate developments.
Meta Platforms [META] shares crashed 7% following court rulings holding the social media giant liable for harm to minors, with analysts warning of potential billion-dollar litigation exposure ahead.
Google's breakthrough TurboQuant technology threatens to significantly reduce memory requirements for AI models, sending semiconductor stocks tumbling as investors reassess demand forecasts for memory chips.
Kodiak Sciences stock jumped over 71% following positive late-stage trial data for Zenkuda, its experimental diabetic retinopathy treatment, signaling renewed investor confidence in the biotech firm's pipeline.
Wave Life Sciences experienced a sharp stock decline following disappointing clinical trial data for its experimental obesity treatment at higher doses.
Kodiak Sciences shares surged nearly 69% after its experimental ophthalmology drug achieved primary endpoints in late-stage clinical trials for diabetic eye disease.
Precious metals face sharp selloff as MCX [MCX] reopens following the Ram Navami break, with gold losing ₹4,300 per 10g and silver dropping ₹13,700 per kg amid global weakness.
Gaudium IVF, Saatvik Green Energy, Tolins Tyres, and two other companies will see their IPO lock-in periods expire tomorrow, potentially triggering significant trading activity and volatility in the market.
The Nifty 50 has witnessed a sharp recovery of nearly 800 points over two trading sessions as market participants reassess geopolitical risks following US-Iran tension easing. However, crude oil volatility and external headwinds remain critical factors to monitor.
Banking sector valuations have turned compelling following recent geopolitical tensions and market corrections. Analysts highlight ICICI Bank, SBI, and Federal Bank as potential opportunities as PSU banks trade at significant discounts.
A select group of penny stocks delivered spectacular returns in FY26, with three emerging as multibaggers. Explore which low-priced stocks captured massive gains and what this means for risk-conscious investors.
Smallcap equities faced severe headwinds in FY26 as geopolitical tensions, tariff concerns, and valuation pressures led to massive selloffs. Investor portfolios holding these securities experienced significant erosion.
The Nifty Realty index has declined 22% in 2026 amid IT layoffs and geopolitical tensions. Market experts suggest selective accumulation of quality real estate stocks ahead of the RBI's April monetary policy meeting.
Precious metals rally as market sentiment improves over potential US-Iran de-escalation. Spot gold climbs 0.7% while silver gains ground amid cautious optimism.
BlueStone Jewellery [BLUESTONE] has gained 15% in a month as investors grow confident in its expansion strategy and improving unit economics. The company's scaling model is showing promising results with over half its stores now generating substantial annual revenues.
Arm Holdings [ARM] stock jumps nearly 20% following the announcement of custom AI processors developed in partnership with Meta Platforms, positioning the company for substantial revenue growth in the semiconductor sector.
Super Micro Computer shares have staged a partial recovery, gaining 9% on March 25 after a steep 33% plunge triggered by an AI chip export investigation. However, monthly losses remain significant.
Corcept Therapeutics shares rallied 32% following FDA approval of Lifyorli for platinum-resistant ovarian cancer, offering new hope for advanced cancer patients unresponsive to conventional therapies.